^
    Back
    Association details:
    Biomarker:BCL2 N103E
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

    Published date:
    11/06/2019
    Excerpt:
    In 7/10 (70%) patients, BCL2 mutations in addition to the Gly101Val were detected. Recurrent mutations (detected in more than one patient) were Asp103Tyr, Asp103Glu, Arg107_Arg110dup, and Val156Asp….In summary, we have extended the landscape of acquired candidate resistance mutations occurring in patients treated with VEN to include four novel recurrent BCL2 mutations.
    DOI:
    https://doi.org/10.1182/blood-2019-125457